Download presentation
Presentation is loading. Please wait.
Published byMartta Aho Modified over 5 years ago
1
Achievement of MDA over 144 weeks in patients initially receiving adalimumab or placebo during the double-blind period. Achievement of MDA over 144 weeks in patients initially receiving adalimumab or placebo during the double-blind period. Data are presented as observed (solid lines) and using NRI (dashed lines). Patients who escalated to weekly dosing on or after week 36 were counted as non-responders. Numbers of patients at each study visit are presented below the graph. ADA, adalimumab; MDA, minimal disease activity; NRI, non-responder imputation; OBS, as observed; PBO, placebo. Philip J Mease et al. RMD Open 2017;3:e000415 Copyright © BMJ Publishing Group & EULAR. All rights reserved.
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.